Philippe Dro has joined Adjuvant Capital as a partner to help the US firm identify investment opportunities across Europe. Dr Dro has worked in the biopharma and medical device sectors for more than 25 years including as chief executive of GlycoVaxyn AG, a Swiss vaccine company acquired by GlaxoSmithKline in 2015. He currently serves as chair of Scenic Biotech BV, a genetic medicines company based in the Netherlands, chair of the Swiss medical device company Luciole Medical AG and chair at LimmaTech Biologics AG, a bioconjugate vaccine company. Dr Dro will be based in Zurich where Adjuvant has an office.
Adjuvant Capital announced the appointment on 29 April 2021.
Copyright 2021 Evernow Publishing Ltd